62332-237 NDC - VARDENAFIL HYDROCHLORIDE

Drug Information

  • Product NDC: 62332-237
  • Proprietary Name: VARDENAFIL HYDROCHLORIDE
  • Non Proprietary Name: VARDENAFIL HYDROCHLORIDE
  • Active Ingredient(s): 5 mg/1 VARDENAFIL HYDROCHLORIDE
  • Administration Route(s): ORAL
  • Dosage Form(s): TABLET, FILM COATED
  • Pharmacy Class(es): Phosphodiesterase 5 Inhibitor [EPC]; Phosphodiesterase 5 Inhibitors [MoA]

Labeler Information

Field Name Field Value
Labeler Name: Alembic Pharmaceuticals Inc.
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: ANDA214031
Marketing Category: ANDA
Start Marketing Date:8/5/2020

Package Information

No. Package Code Package Description Billing Unit
162332-237-3030 TABLET, FILM COATED in 1 BOTTLE (62332-237-30)
262332-237-31100 TABLET, FILM COATED in 1 BOTTLE (62332-237-31)

NDC Record

Field Name Field Value Definition
PRODUCT NDC62332-237The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEVARDENAFIL HYDROCHLORIDEThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEVARDENAFIL HYDROCHLORIDEThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMETABLET, FILM COATEDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE8/5/2020This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMEANDAThis is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
APPLICATION NUMBERANDA214031This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEAlembic Pharmaceuticals Inc.Name of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMEVARDENAFIL HYDROCHLORIDEName of Company corresponding to the labeler code segment of the Product NDC.
ACTIVE NUMERATOR STRENGTH5 
ACTIVE INGRED UNITmg/1 
PHARM CLASSESPhosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA] 

Download Record

Download this NDC record record in Text format: Export

Download this NDC record record in Excel (CSV) format: Export

Download this NDC record record in XML format: Export

This page was last updated on: 12/19/2025